Biotech Values

[srsmgja]

Thank you Genisi for providing that complete information.

Remember that as of 1/02/09 Teva raised the price of Copaxone another 10%. That would bring the price to roughly in line with the price of the interferons and still 10% below Tysabri.

That will also start Teva out of the gate with another 250M in yearly sales of Copaxone assuming no unit growth and no additonal price increases for the remainder of 2009.

Tysabri has been the best thing that ever happen for the interferons and Copaxone. Even though collectively they have lost 7.5% market share, they have made up that shortfall many fold by raising prices by 75-95% over the last four years.

It is going to be interesting to see how they maintain these remarkable growth rates. Will the market bear continued double digit price increases year after year?